We aimed to compare the prevalence and associated factors of anti-α3Gal IgE using the 70BP and bTG assays in a cohort of healthy blood donors and in patients with head and neck cancer treated with cetuximab and to determine their predictive values for anaphylaxis in cetuximab-treated patients. The gene discussed is IGHE; the disease is head and neck cancer.